A work in progress: The clinical development of histone deacetylase inhibitors

Epigenetics

Volumn 3, Issue 3, 2008, Pages 164-171

  Marsoni, Silvia ^a   Damia, Giovanna ^b   Camboni, Gabriella ^c  

^a SENDO Foundation   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Ethical Oncology Science (EOS) SpA   (Italy)

Author keywords

Activity; Chromatin remodelling; Clinical development; HDAC inhibitor; Toxicity

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BELINOSTAT; BEXAROTENE; DEPSIPEPTIDE; FK 288; GEMCITABINE; GYRASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; JJ 26481585; LAQ 82411; MGCD 103D 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PANOBINOSTAT; PCI 24781; PDX 101; PIVALOYLOXYMETHYL BUTYRATE; RETINOIC ACID; SB 939; SMALL INTERFERING RNA; SNDX 275; VALPROIC ACID; VORINOSTAT;

ANEMIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; BONE MARROW SUPPRESSION; BRAIN DISEASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL TRANSFORMATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOSKELETON; DEACETYLATION; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SYNTHESIS; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; EPIGENETICS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRURITUS; QT PROLONGATION; REPEATED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SUDDEN DEATH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY TESTING; UNSTEADINESS; VOMITING;

EID: 49249116407     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.3.3.6253     Document Type: Conference Paper

References (42)

1. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14:65-76.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
3. Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002; 86:41-65.
4. Mai A. Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25:261-309.
5. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001; 48:17-9.
6. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14:1497-511.
7. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4:549-51.
8. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-52.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84.
10. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51.
11. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005; 68:917-32.
12. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-49.
13. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23:3971-93.
14. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73:417-35.
15. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family functional implications of phylogenetic analysis. J Mol Biol 2004; 338:17-31.
16. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21:2672-81.
17. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110:479-88.
18. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5:981-9.
19. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96:293-304.
20. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005: 2:150-7.
21. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002; 64:1079-90.
22. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101:3236-9.
23. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of hear shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280:26729-34.
24. Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006: 6:1205-14.
25. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115:727-38.
26. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008; 7:7-10.
27. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG. Inhibitors of histone deacetylases induce rumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11:71-6.
28. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 2006; 103:15540-5.
29. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102:673-8.
30. Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006; 5:2430-5.
31. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005; 9:809-24.
32. Michaelis M, Doerr HW, Cinatl J Jr. Valproic acid as anti-cancer drug. Curr Pharm Des 2007; 13:3378-93.
33. Duenas-Gonzalez. A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; (Epub ahead of prim).
34. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25:3884-91.
35. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostar: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84-90.
36. Duvic M, Vu J. Vorinostar: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111-20.
37. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-31.
38. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9:3578-88.
39. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostar (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31-9.
40. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109-15.
41. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF, Zwiebel J, Buckner JC. N047B: NCCTG phase II trial of vorinostar (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I 2007; 25:2004.
42. Kirschbaum M, Zain J, Popplewell L, Pullarkat V, Obadike N, Frankel P, Zwiebel J, Forman S, Newn E, Gandara D. Phase 2 of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma A California Cancer Consortium study. J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I 2007; 25:18515.